Telomerase encoding DNA vaccine
US12064474B2 · kind B2 · utility
0Cited by
8References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2018 |
| Grant date | Aug 20, 2024 |
| Priority date | — |
| Expiry date | May 7, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/07049
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.